Sign in

CIK 0001640266

  • Accelerated filer
  • Smaller reporting company

Voyager Therapeutics, Inc.

Sign in to watch
Ticker
VYGR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 857-259-5340
Business address
75 HAYDEN AVENUE, LEXINGTON, MA, 02421
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2020-01-21 Turenne Andre President & CEO Sale −10,705 $13.36 $143K 85,545
2019-06-13 PAUL STEVEN M Director Grant or award · Stock Option (Right to Buy) +15,000 15,000
2019-06-13 KARSEN PERRY A Director Grant or award · Stock Option (Right to Buy) +15,000 15,000
2019-06-13 PIERCE GLENN Director Grant or award · Stock Option (Right to Buy) +15,000 15,000
2019-06-13 GERAGHTY JAMES A Director Grant or award · Stock Option (Right to Buy) +15,000 15,000
2019-06-13 LEVIN MARK J Director Grant or award · Stock Option (Right to Buy) +15,000 15,000
2019-06-13 Higgins Michael J Director Grant or award · Stock Option (Right to Buy) +15,000 15,000
2019-06-13 Hyman Steven Director Grant or award · Stock Option (Right to Buy) +15,000 15,000
2019-06-13 DIXON WENDY L Director Grant or award · Stock Option (Right to Buy) +15,000 15,000
2019-05-20 Khwaja Omar Grant or award +30,000 30,000
2019-05-20 Khwaja Omar Grant or award · Stock Option (Right to Buy) +170,000 170,000
2019-04-01 Hesslein Robert W. Senior VP & General Counsel Grant or award +28,125 28,125
2019-04-01 Hesslein Robert W. Senior VP & General Counsel Grant or award · Stock Option (Right to Buy) +168,750 168,750
2019-03-12 NEUROCRINE BIOSCIENCES INC 10% owner Purchase +4,179,728 $11.96 $50.0M 4,179,728
2019-01-11 Turenne Andre President & CEO Grant or award +96,250 96,250
2019-01-11 Turenne Andre President & CEO Grant or award · Stock Option (Right to Buy) +192,500 192,500
2019-01-11 Sah Dinah Ph.D. Chief Scientific Officer Grant or award +25,000 163,688
2019-01-11 Sah Dinah Ph.D. Chief Scientific Officer Grant or award · Stock Option (Right to Buy) +50,000 50,000
2019-01-11 Ottmer Matthew P. Chief Operating Officer Grant or award +30,000 30,000
2019-01-11 Ottmer Matthew P. Chief Operating Officer Grant or award · Stock Option (Right to Buy) +60,000 60,000

Page 14 of 19 · 368 trades